RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes

Clinical outcomes for high-risk neuroblastoma patients remains poor, with only 40–50% 5-Year overall survival (OS) and <10% long-term survival. The ongoing acquisition of genetic/molecular rearrangements in undifferentiated neural crest cells may endorse neuroblastoma progression. This study reco...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Faizan H., Pandian, Vijayabaskar, Ramraj, Satish Kumar, Aravindan, Sheeja, Natarajan, Mohan, Azadi, Seifollah, Herman, Terence S., Aravindan, Natarajan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742193/
https://www.ncbi.nlm.nih.gov/pubmed/26375249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742193/
https://www.ncbi.nlm.nih.gov/pubmed/26375249

Ejemplares similares